United StatesIn-vitro Cancer Diagnostics Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

In-vitro Cancer Diagnostics Market is growing at a CAGR of 3.9% during the forecast period (2023-2030).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/in-vitro-cancer-diagnostics-market?sb

Key Development:

United States: Recent In‐Vitro Cancer Diagnostics Developments

✅ In January 2026, Cleveland Diagnostics received FDA approval for its IsoPSA® in‐vitro diagnostic kit, a blood‐based prostate cancer test designed to aid clinicians in biopsy decision making for men aged 50 and above with elevated PSA levels, advancing early detection options.

✅ In December 2025, U.S. diagnostic innovators and sequencing partners announced expanded collaborations to commercialize advanced liquid biopsy and genomic cancer assays, including co‐marketing efforts for precision oncology tests that enhance tumour profiling and recurrence monitoring.

✅ In December 2025, Adaptive Biotechnologies' clonoSEQ® MRD test for measurable residual disease in blood cancers featured in 89 abstracts at the 67th ASH Annual Meeting, highlighting widespread clinical validation and expanded use across multiple hematologic malignancies.

✅ In November 2025, SOPHiA GENETICS and sequencing partners integrated end‐to‐end oncology analytics workflows, combining AI‐driven platforms with next‐generation sequencing systems to support enhanced molecular cancer diagnostics worldwide.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=in-vitro-cancer-diagnostics-market

Japan: Recent In‐Vitro Cancer Diagnostics Developments

✅ In November 2025, the Japanese Foundation for Cancer Research (JFCR), NEC Corporation, and Taiho Pharmaceutical launched a joint initiative on whole‐genome‐based cancer research, supporting shared neoantigen discovery to improve individualized diagnostics and future cancer vaccine development.

✅ In late 2025, genomic‐based cancer research collaboration results in Japan confirmed new methods for identifying neoantigens using proprietary AI technology, advancing frameworks for next‐generation personalized in‐vitro cancer diagnostic approaches.

✅ In Oct/Nov 2025, research and clinical networks such as LC‐SCRUM‐CD expanded precision oncology screening capabilities nationwide, under Japan's precision medicine initiatives to integrate genomic profiling into in‐vitro testing workflows.

✅ In recent months, Japanese cancer diagnostics innovation has been bolstered by AI‐driven technologies and advanced biomarker detection tools, reflecting a rising trend in precise in‐vitro cancer tests and early‐detection approaches across the country's clinical and research landscapes.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/in-vitro-cancer-diagnostics-market?sb

Key Players:

1. F. Hoffmann‐La Roche AG:
Roche, the largest global IVD player, has total revenues of USD 68-69 billion (2024), with its diagnostics division contributing USD 16.8 billion. It leads in oncology diagnostics with advanced molecular and biomarker tests.

2. Abbott Laboratories:
Abbott's total revenue is USD 42.9 billion, with diagnostics around USD 8.5-9 billion. The company is expanding cancer testing via acquisitions like Exact Sciences, offering instruments, assays, and molecular diagnostics.

3. Thermo Fisher Scientific, Inc.:
With total revenue of USD 42.9 billion, Thermo Fisher is a top IVD player. Its molecular and oncology-focused diagnostics portfolio includes instruments, reagents, and tests supporting cancer diagnostics.

4. Danaher Corporation (Beckman Coulter, Inc.):
Danaher's diagnostics segment (41% of total revenue) provides instruments, reagents, and molecular platforms for oncology testing through Beckman Coulter, making it a major IVD player.

5. Becton, Dickinson and Company (BD):
BD's diagnostics and biosciences units generate USD 3.3 billion, offering instruments and assays for laboratory and oncology testing, while expanding through strategic spin-offs.

6. QIAGEN N.V.:
QIAGEN has USD 2.2 billion revenue, specializing in molecular diagnostics, sample prep, and assays used in biomarker detection and precision oncology testing.

7. Sysmex Corporation:
Sysmex generates USD 3.5 billion, focusing on IVD instruments and hematology solutions, widely used in cancer monitoring and lab diagnostics.

8. Bio-Rad Laboratories, Inc.:
Bio-Rad's revenue is USD 2.8 billion, providing clinical diagnostics and molecular/immunoassay platforms for cancer research and lab testing.

9. bioMérieux SA:
bioMérieux reports USD 3.3 billion, offering diagnostic solutions including molecular and immunoassay technologies for infectious disease and oncology screening.

10. Siemens AG (Siemens Healthineers):
Siemens Healthineers' diagnostics segment is USD 0.9 billion, providing lab instruments, imaging, and IVD solutions used in oncology testing globally.

Key Segments:

By Product Type

The market is segmented into Reagents, Instruments, and Others. Reagents dominate with approximately 45% share, driven by their frequent use in molecular diagnostics, clinical chemistry, and point-of-care testing. Instruments hold 35%, supported by increasing adoption of automated diagnostic analyzers and advanced testing equipment. Others (consumables, kits, and software) contribute 20%, fueled by supportive diagnostic solutions and integration with laboratory information systems.

By Technique Type

The market includes Molecular Diagnostics, Clinical Chemistry, Point-Of-Care Testing, and Others. Molecular Diagnostics leads with 40% share, due to growing demand for early disease detection, personalized medicine, and pathogen testing. Clinical Chemistry accounts for 30%, driven by routine health screenings and chronic disease monitoring. Point-Of-Care Testing (POCT) holds 20%, supported by rapid testing needs in hospitals, clinics, and remote healthcare facilities. Others (immunology, hematology) make up 10%.

By End-User

Key end-users include Hospital-Associated Labs, Cancer Research Institutes, Diagnostic Imaging Centers, and Others. Hospital-Associated Labs dominate with 50% share, reflecting the high volume of routine and specialized testing. Cancer Research Institutes account for 20%, driven by oncology-focused molecular diagnostics and research initiatives. Diagnostic Imaging Centers contribute 15%, integrating molecular and biochemical testing with imaging workflows. Others (independent labs, academic research labs) hold 15%.

By Region

North America is the largest region, with a 35% share, due to high healthcare expenditure, early adoption of advanced diagnostics, and robust R&D infrastructure. Europe contributes 30%, driven by well-established healthcare systems and strong regulatory frameworks. Asia Pacific is the fastest-growing region, accounting for 25%, fueled by increasing healthcare access, government initiatives, and rising demand for diagnostic testing in China, India, Japan, and South Korea. South America and Middle East & Africa hold 5% and 5%, respectively, supported by gradual expansion of diagnostic infrastructure and rising disease awareness.

FAQ

Q: What is the growth rate of the In-vitro Cancer Diagnostics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3.9% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.